Endurance Announces CEO Transition Plan Board Initiates

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
239
Endurance Announces CEO Transition Plan

Board Initiates Search for Successor; Hari Ravichandran to Remain CEO Until Successor is Appointed

Company Confirms GAAP Revenue, Adjusted EBITDA, and Free Cash Flow Guidance for 2017

BURLINGTON, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Endurance International Group (NASDAQ: EIGI ) (“Endurance” or the “Company”), a leading provider of cloud based platform solutions, today announced that its Board of Directors and its Chief Executive Officer Hari Ravichandran have adopted a CEO transition plan. Mr. Ravichandran will remain CEO and serve as a Board member while the Company conducts a search to identify his successor. 

As a founder of the Company, Mr. Ravichandran has led the Company to many milestones, including the Company’s IPO in 2013 and last year’s acquisition of Constant Contact.  Endurance generated over $1 billion of revenue in 2016 under Mr. Ravichandran’s leadership.

“The Board thanks Hari for his vision and the entrepreneurial spirit that led to Endurance’s growth into the global family of web service providers it is today,” said James C. Neary, Chairman of the Board of Directors, Endurance International Group. “The Board and Hari have been engaged in a dialogue over an extended period of time about an eventual transition of his leadership, and will work together to bring on a CEO who can take Endurance to the next level.”

Given the significant expansion of the business, the substantial focus on free cash flow generation and risk management, and the previously disclosed SEC investigation regarding non-GAAP metrics, the Board decided, and Mr. Ravichandran agreed, to accelerate the succession planning. They believe that finding a CEO with a breadth of experience growing complex organizations will enable Endurance to reach its next set of milestones. The Board has retained Heidrick & Struggles, an international executive search firm, to assist with the search process for a new CEO.

“When I started Endurance over 20 years ago, I never imagined the joys, challenges, and learnings that would come from travelling the entrepreneurial road. Today, I’m proud to say we have more than 4,000 talented employees working on behalf of five million subscribers to our services around the world who rely on Endurance for their online presence,” said Ravichandran.  “My number one priority has always been to do what is best for Endurance, our employees and our shareholders, and I am pleased that the Board and I are aligned on the qualities our next CEO needs. I look forward to working with my fellow Board members to identify a successor who can continue to drive growth by powering small businesses worldwide.”

Business Outlook

The Company also announced today that it is confirming its previously announced 2017 GAAP revenue, adjusted EBITDA and free cash flow guidance.

The Company's expectations for the full year 2017 are as follows:

  2016 Actual As reported   Fiscal 2017 Guidance
GAAP revenue $1.111 billion   4 – 5% increase
Adjusted EBITDA $288 million   12 – 14% increase
Free cash flow $112 million   ~35% increase

Adjusted EBITDA and free cash flow are non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to their most comparable measure calculated in accordance with GAAP is provided in the financial statement tables included at the end of this press release.

* Percentage increases shown in the “Guidance” column represent percentage increases over 2016 figures shown in the adjacent column.

Non-GAAP Financial Measures

In addition to our financial information presented in accordance with GAAP, we use adjusted EBITDA and free cash flow, which are non-GAAP financial measures, to evaluate the operating and financial performance of our business, identify trends affecting our business, develop projections and make strategic business decisions.  A non-GAAP financial measure is a numerical measure of a company’s operating performance, financial position or cash flow that includes or excludes amounts that are included or excluded from the most directly comparable measure calculated and presented in accordance with GAAP.

Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP and exclude expenses that may have a material impact on our reported financial results. For example, adjusted EBITDA excludes interest expense, which has been and will continue to be for the foreseeable future a significant recurring expense in our business. The presentation of non-GAAP financial information is not meant to be considered in isolation from, or as a substitute for, the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the additional information about adjusted EBITDA and free cash flow shown below, including the reconciliations of these non-GAAP financial measures to their comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a non-GAAP financial measure that we calculate as net (loss) income, excluding the impact of interest expense (net), income tax expense (benefit), depreciation, amortization of other intangible assets, stock-based compensation, restructuring expenses, transaction expenses and charges, (gain) loss of unconsolidated entities, and impairment of other long-lived assets. We view adjusted EBITDA as a performance measure and believe it helps investors evaluate and compare our core operating performance from period to period.

Free Cash Flow, or FCF , is a non-GAAP financial measure that we calculate as cash flow from operations less capital expenditures and capital lease obligations. We believe that FCF provides investors with an indicator of our ability to generate positive cash flows after meeting our obligations with regard to capital expenditures (including capital lease obligations).

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the CEO transition plan and the Company’s financial guidance for the fiscal year 2017. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts, and statements identified by words such as “expects,” “intends,” “will,” “may,” and variations of such words or words of similar meaning and the use of future dates. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that these plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation: our ability to identify, attract, engage and transition to a new CEO; that we may be unable to successfully enhance the customer product and service experience and improve customer satisfaction and retention through operational and infrastructure improvements; that we may encounter difficulties or delays in our efforts to build brand awareness of our key brands; that we may be unable to drive revenue growth by increasing ARPS through cross-selling and other product-related initiatives; that we may continue to experience decreases in our subscriber base; an adverse impact on our business from litigation or regulatory proceedings; an adverse impact on our business from our substantial indebtedness and the cost of servicing our debt; the rate of growth of the Small and Medium Business (“SMB”) market for our solutions; that we may be unable to increase sales to our existing subscribers, or retain our existing subscribers; system or Internet failures; that we may be unable to maintain or improve our competitive position or market share; and other risks set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on February 24, 2017 and other reports we file with the SEC. We assume no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Endurance International Group

Endurance International Group Holdings, Inc. (NASDAQ: EIGI ) (em)Powers millions of small businesses worldwide with products and technology to vitalize their online web presence, email marketing, mobile business solutions, and more. The Endurance family of brands includes: Constant Contact, Bluehost, HostGator, iPage, Domain.com, BigRock, SiteBuilder and SinglePlatform, among others. Headquartered in Burlington, Massachusetts, Endurance employs more than 4,000 people across the United States, Brazil, India and the Netherlands. For more information, visit:   www.endurance.com .

Endurance International Group and the compass logo are trademarks of The Endurance International Group, Inc.  Other brand names of Endurance International Group are trademarks of The Endurance International Group, Inc. or its subsidiaries.

GAAP to Non-GAAP Reconciliation of Fiscal Year 2017 Guidance - Adjusted EBITDA

The following table reflects the reconciliation of fiscal year 2017 estimated net loss calculated in accordance with GAAP to fiscal year 2017 guidance for adjusted EBITDA at the high end of the guidance range (i.e. assuming a 12% increase over 2016 adjusted EBITDA as reported). All figures shown are approximate.

($ in millions) Twelve Months Ending December 31, 2017
Estimated net loss $ (91 )  
Estimated interest expense (net) 148    
Estimated income tax expense (benefit) 10    
Estimated depreciation 56    
Estimated amortization of acquired intangible assets 137    
Estimated stock-based compensation 57    
Estimated restructuring expenses 8    
Estimated transaction expenses and charges —    
Estimated (gain) loss of unconsolidated entities —    
Estimated impairment of other long-lived assets —    
Adjusted EBITDA guidance $ 325  

GAAP to Non-GAAP Reconciliation of Fiscal Year 2017 Guidance  - Free Cash Flow

The following table reflects the reconciliation of fiscal year 2017 estimated cash flow from operations calculated in accordance with GAAP to fiscal year 2017 guidance for free cash flow. All figures shown are approximate.

($ in millions) Twelve Months Ending December 31, 2017
Estimated cash flow from operations $ 205    
Estimated capital expenditures and capital lease obligations (55 )  
Free cash flow guidance $ 150  

Investor Contact: Angela White Endurance International Group (781) 852-3450 ir@endurance.com Press Contact: Lark-Marie Anton Endurance International Group (646) 887-7272 press@endurance.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

b1BANK Partners with Spiral to Enhance Community Banking Impact

Updated Category News Views 97

Enhanced Financial Wellness through Partnership NEW YORK--Today, Spiral, a personalized banking platform, announced a significant partnership with b1BANK, established as a community-focused banking institution. Through this collaboration, the two organizations aim to enhance financial wellness for customers, leveraging b1BANK's dedication to innovative banking solutions...

Continue Reading
AM Best Explores Trends Influencing For-Hire Trucking Industry

Updated Category News Views 168

Insights from AM Best's Latest Webinar on Trucking Trends Viewers can now delve into the highlights from the enlightening webinar hosted by AM Best, titled "For-Hire Trucking: The Risky Road Ahead." This event focused on the intricacies and challenges within the transportation-for-hire trucking sector, providing expert insights into risk management strategies and the...

Continue Reading
BitMart's Creative Campaign to Ignite Offline Crypto Engagement

Updated Category News Views 135

Introducing the Fox Hunt Delivery Campaign BitMart, a leading global cryptocurrency exchange, is excited to announce the launch of the Fox Hunt Delivery Campaign, a unique initiative aimed at boosting cryptocurrency adoption through engaging offline activities. This campaign offers an exciting chance for participants to earn USDT rewards simply by introducing new users to...

Continue Reading
Trinity Capital Inc. Fuels Alt Platform's Growth with $40M Credit

Updated Category News Views 273

Trinity Capital Inc. Supports Alt with Significant Credit Facility Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, is thrilled to announce a groundbreaking agreement with Alt, providing up to $40 million through an asset-based revolving credit facility. This funding aims to bolster Alt's innovative marketplace tailored for trading card...

Continue Reading
Everest Medicines Achieves Record Revenue and Growth in 2024

Updated Category News Views 506

Everest Medicines Achieves Remarkable Financial Success Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic...

Continue Reading